James Oliff - CME Independent Director

CME Stock  USD 215.60  2.72  1.28%   

Director

Mr. James E. Oliff is an Independent Director of CME Group Inc. Mr. Oliff was a member of CME for more than 35 years. Mr. Oliff served as our Vice Chairman from 2002 until 2007 and as our Second Vice Chairman from 1998 until 2002. Mr. Oliff has also served as President of FILO Corporationration, a floor brokerage business, since 1982. Mr. Oliff previously served as Executive Director of International Futures and Options Associates from 1996 to 2005, as President and CEO of FFast Trade U.S., LLC from 2001 to 2005, as Chairman and CEO of FFastFill Inc. from 2003 to 2005 and as FFastFills COO from 2001 to 2003. He also served as President of LST Commodities, LLC, an introducing broker, from 1999 until 2002. Mr. Oliff is the Chairman of the CME Group Foundation. since 2007.
Age 66
Tenure 17 years
Address 20 South Wacker Drive, Chicago, IL, United States, 60606
Phone312 930 1000
Webhttps://www.cmegroup.com
Oliff previously served as Executive Director of International Futures and Options Associates from 1996 to 2005, as President and CEO of FFast Trade U.S., LLC from 2001 to 2005, as Chairman and CEO of FFastFill Inc. from 2003 to 2005 and as FFastFill’s COO from 2001 to 2003. He also served as President of LST Commodities, LLC, an introducing broker, from 1999 until 2002. He currently serves as a member of the advisory board for the MS Program in Financial Engineering at Kent State University and the advisory board of The Review of Futures Markets.

CME Management Efficiency

The company has Return on Asset of 0.0142 % which means that on every $100 spent on assets, it made $0.0142 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1203 %, implying that it generated $0.1203 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.
The company has 3.88 B in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. CME Group has a current ratio of 1.0, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Debt can assist CME until it has trouble settling it off, either with new capital or with free cash flow. So, CME's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CME Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CME to invest in growth at high rates of return. When we think about CME's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Fred HatfieldIntercontinental Exchange
63
Judith SprieserIntercontinental Exchange
67
Paul PrydeQuotemedia
N/A
Joseph LairdFactSet Research Systems
69
Laurie SiegelFactSet Research Systems
64
Siew ChoyFactSet Research Systems
54
Thomas NoonanIntercontinental Exchange
60
Vincent TeseIntercontinental Exchange
77
Scott BilleadeauFactSet Research Systems
58
Ann CairnsIntercontinental Exchange
61
Frederic SalernoIntercontinental Exchange
77
Scott MillerFactSet Research Systems
46
Callum McCarthyIntercontinental Exchange
70
Lee ShavelFactSet Research Systems
53
William HagueIntercontinental Exchange
60
Sheila JordanFactSet Research Systems
56
Terrence MartellIntercontinental Exchange
68
James McGonigleFactSet Research Systems
57
Duriya FarooquiIntercontinental Exchange
44
Robert ReidIntercontinental Exchange
80
Joseph ZimmelFactSet Research Systems
67
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois. CME operates under Financial Data Stock Exchanges classification in the United States and is traded on NASDAQ Exchange. It employs 3480 people. CME Group (CME) is traded on NASDAQ Exchange in USA. It is located in 20 South Wacker Drive, Chicago, IL, United States, 60606 and employs 3,565 people. CME is listed under Financial Exchanges & Data category by Fama And French industry classification.

Management Performance

CME Group Leadership Team

Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ana Dutra, Independent Director
Daniel Glickman, Independent Director
Howard Siegel, Independent Director
Kathleen Cronin, Senior Managing Director, General Counsel, Corporate Secretary
Dennis Chookaszian, Independent Director
Kendal Vroman, Chief Officer
Michel Everaert, MD EMEA
Steven Wollack, Independent Director
William Miller, Independent Director
Derek Sammann, Senior Managing Director - Financial Products and Services
Cees Vermaas, Managing Director & CEO of CME Europe Limited
Gedon Hertshten, Independent Director
Sean Keating, MD Office
Elizabeth Cook, Independent Trustee
Daniel Kaye, Director
Douglas Monieson, Independent Director
William Knottenbelt, Senior Managing Director, Europe, Middle East, Africa (EMEA)
John Pietrowhicz, Senior Managing Director - Business Development and Corporate Finance
Jeffrey Bernacchi, Independent Director
James Oliff, Independent Director
Sunil Cutinho, President - CME Clearing
Julie Holzrichter, COO and Sr. Managing Director
Timothy Bitsberger, Independent Director
Bryan Durkin, Chief Commercial Officer and Sr. Managing Director
Patrick Maloney, Independent Director
Dennis Suskind, Independent Director
Alex Pollock, Lead Independent Director
Leo Melamed, Chairman Emeritus
Charles Carey, Vice Chairman of the Board
Hilda Piell, Chief Human Resource Officer, Senior Managing Director
Kimberly Taylor, President of Global Operations, Technology and Risk
David Wescott, Independent Director
Anita Liskey, Senior Communications
Edemir Pinto, Independent Director
Deborah Lucas, Independent Director
John Sandner, Director
Jack Tobin, Chief Accounting Officer, Managing Director
Larry Gerdes, Independent Director
Phupinder Gill, CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee
Linda Rich, Senior Managing Director - Government Relations and Legislative Affairs
Terry Savage, Independent Director
Bruce Johnson, Independent Director
Jonathan Marcus, Senior Counsel
Julie Winkler, Senior Managing Director - Research and Product Development
Ronald Pankau, Independent Director
Kevin Kometer, CIO, Senior Managing Director
Robert Zagotta, Senior Managing Director - Products and Services
Lynne Fitzpatrick, Chief Officer
Yra Harris, Director
Jill Harley, Managing Director
Terrence Duffy, Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee
Edward Gogol, Managing Solutions
Michael Spencer, Director
John Peschier, Managing Relations
Jason Weller, Managing Strategy
Martin Gepsman, Independent Director
William Hobert, Independent Trustee
Christopher Bowen, Chief MD
Elizabeth Gisch, Managing Management
Sean Tully, Senior Managing Director - Interest Rates, OTC Products
Eileen Keeve, Managing Devel
William Shepard, Independent Director
Kevin Lennon, Managing Estate

CME Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with CME

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CME position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CME will appreciate offsetting losses from the drop in the long position's value.

Moving together with CME Stock

  0.81MORN MorningstarPairCorr

Moving against CME Stock

  0.67DHIL Diamond Hill InvestmentPairCorr
  0.63MCBC Macatawa Bank Fiscal Quarter End 31st of March 2024 PairCorr
  0.61MBCN Middlefield Banc Fiscal Quarter End 31st of March 2024 PairCorr
  0.56VALU Value LinePairCorr
  0.51SPGI SP Global Financial Report 25th of April 2024 PairCorr
The ability to find closely correlated positions to CME could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CME when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CME - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CME Group to buy it.
The correlation of CME is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CME moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CME Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CME can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for CME Stock analysis

When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.276
Dividend Share
4.4
Earnings Share
8.86
Revenue Per Share
15.512
Quarterly Revenue Growth
0.192
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.